- Nominations may be submitted by organizations and individual members of the equine community.
- The award will be given based on the merit of nominations received and might not necessarily be presented each year. The recipient (or a representative) must be available and willing to attend the Equine Canada Awards Gala recognition ceremony. The recipient must be willing to participate in other recognition activities as required, such as interviews with the media. In addition, a news release will be distributed to media across the country and information will be posted to the Equine Canada website and its other communication materials and social media networks.
“We are very pleased to be able to sponsor this award to honor those individuals or organizations who have added so much to the health and wellbeing of horses and ponies in Canada,” Jelle Bergmans, Boehringer-Ingelheim (Canada) Ltd. Product Manager Bovine/Equine. “These fields have expanded so rapidly in the past few years that Boehringer Ingelheim thought it appropriate to be able to recognize those who have made outstanding contributions in these areas. Thank you to Equine Canada for graciously agreeing to undertake the task of seeking nominations and selecting the recipient.”
The award will incorporate a recognition plaque to belong to the recipient, inclusion of the recipient’s biography in Equine Canada Annual Awards Gala booklet, a complimentary trip to Equine Canada Annual Awards Gala, and a $1000 donation to an equine charity of their choice. This award is jointly supported by Equine Canada and a donation from Boehringer Ingelheim (Canada) Ltd.
Submission Deadline: February 23rd, 2015.
Visit the Health & Welfare section of the Equine Canada website for more details and the nomination form — http://bit.ly/1ysw55J.
About Boehringer Ingelheim
The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates and more than 44,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel medications of high therapeutic value for human and veterinary medicine.